Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer.
Affiliation
The Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BXIssue Date
2015-05
Metadata
Show full item recordAbstract
Antibodies against immune checkpoints including CTLA-4, PD-1 and PD-L1 are increasingly being used in lung cancer. They are associated with novel, immune related toxicities not previously encountered with established treatments for lung cancer including colitis, hepatitis, rashes, neuropathies and other rarer immune mediated toxicities. Although generally these are low grade, there is a potential to be life threatening if not managed promptly. Early recognition of toxicity and institution of management algorithms are key to ensuring patient safety. We review the common toxicities and provide recommendations on their management.Citation
Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer. 2015, 88 (2):117-123 Lung CancerJournal
Lung CancerDOI
10.1016/j.lungcan.2015.02.007PubMed ID
25776466Type
ArticleLanguage
enISSN
1872-8332ae974a485f413a2113503eed53cd6c53
10.1016/j.lungcan.2015.02.007